Assenagon Asset Management S.A. Raises Stock Holdings in Accuray Incorporated (NASDAQ:ARAY)

Assenagon Asset Management S.A. raised its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 127.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 164,999 shares of the medical equipment provider’s stock after buying an additional 92,357 shares during the quarter. Assenagon Asset Management S.A. owned about 0.17% of Accuray worth $297,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of ARAY. SG Americas Securities LLC purchased a new position in Accuray during the 3rd quarter valued at about $59,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Accuray by 13.3% during the second quarter. The Manufacturers Life Insurance Company now owns 44,936 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 5,273 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Accuray in the 2nd quarter worth approximately $30,000. Armistice Capital LLC purchased a new stake in shares of Accuray in the 2nd quarter worth approximately $910,000. Finally, Hsbc Holdings PLC grew its stake in shares of Accuray by 55.1% in the 2nd quarter. Hsbc Holdings PLC now owns 101,683 shares of the medical equipment provider’s stock worth $180,000 after buying an additional 36,108 shares during the last quarter. Institutional investors own 64.08% of the company’s stock.

Accuray Stock Up 1.2 %

Shares of NASDAQ:ARAY opened at $1.75 on Monday. The company has a current ratio of 1.66, a quick ratio of 0.95 and a debt-to-equity ratio of 3.65. The stock has a fifty day simple moving average of $1.91 and a two-hundred day simple moving average of $1.85. Accuray Incorporated has a 12-month low of $1.40 and a 12-month high of $3.05. The stock has a market capitalization of $175.47 million, a price-to-earnings ratio of -10.94 and a beta of 1.40.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported $0.03 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.03. Accuray had a negative return on equity of 33.65% and a negative net margin of 3.48%. The firm had revenue of $134.29 million during the quarter, compared to analyst estimates of $122.80 million. During the same quarter in the previous year, the firm earned ($0.03) EPS. On average, research analysts anticipate that Accuray Incorporated will post -0.01 earnings per share for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.